Genetics study is the exploration of genes, genetic variation as well as hereditary in humans and animals. Genetics research is a field in biology that explores the inheritance of diseases as well as characteristics of living organisms. Researchers and scientists have massively invested in the study of genetics in a bid to find the causative agents of diseases like cancer. Clay Siegall is a good example of one of the many research scientists who has taken the time to study genetic variation with the aim of finding treatment therapies as well as drugs for cancer.
Clay’s career began in college when a relative fell sick, and the chemotherapy session took a toll on the patient. As he describes the series of events in the interview, the family member was in pain. His passion for saving lives developed at that point. Consequently, he began to explore science and biology.
In 1998, Clay established Seattle Genetics with the aim of finding treatment for cancer and other life-threatening ailments. The company is biotech based, and it specializes in the generation of therapeutic drugs. As the chief executive officer of the company, his roles include managing the team of scientist researchers and making decisions on behalf of the management. He is the brain behind all operations in the company. Seattle Genetics focuses on using modern state of the art technology and resources in finding proper and painless treatment for patients.
Recently, the company launched ADCETRIS, a drug antibody conjugate that received the first FDA approval. ADCETRIS has since paved the way for Seattle Genetics to inject a pipe for medicinal products into various markets. As proof that ADCETRIS is a viable treatment option, it has been approved in over fifty countries including Canada. The drug has aided in the development of over twenty drugs in the market with most of them leading to business partnerships between Seattle Genetics and pharmaceutical firms. Through it all, the alumnus of the George Washington University has been the head cheerleader of the company.
Siegall is the chief executive officer of Seattle Genetics. He is dedicated to finding treatment solutions for cancer. He graduated from the University of Maryland with a degree in zoology. He also has a Ph.D. in genetics.